CD274 and non-small cell lung carcinoma: And the advent of immunotherapeutic agents targeting programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1), also known as one of immunoregulatory checkpoint inhibitors (ICIs), altered thoroughly the management of patients with progressive or metastatic NSCLC.